Calan Sr

Cluster Headache, prophylaxis of Cluster headaches, Angina, Unstable + 7 more

Treatment

3 FDA approvals

20 Active Studies for Calan Sr

What is Calan Sr

Verapamil

The Generic name of this drug

Treatment Summary

Verapamil is a medication used to lower high blood pressure, control heart arrhythmias, and treat chest pain. It was the first calcium channel blocker to become available as a treatment in the 1960s. Verapamil belongs to a group of drugs known as non-dihydropyridine calcium channel blockers, which includes drugs like diltiazem and flunarizine. It is a combination of two versions of the drug (called enantiomers), one of which is more powerful but breaks down faster in the body.

Calan

is the brand name

image of different drug pills on a surface

Calan Sr Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Calan

Verapamil

1984

357

Approved as Treatment by the FDA

Verapamil, also called Calan, is approved by the FDA for 3 uses which include Atrial Fibrillation or Flutter and Hypertensive disease .

Atrial Fibrillation or Flutter

Used to treat Atrial Fibrillation or Flutter in combination with Digitoxin

Hypertensive disease

Used to treat High Blood Pressure (Hypertension) in combination with Trandolapril

Heart Rate

Used to treat Heart Rate in combination with Digitoxin

Effectiveness

How Calan Sr Affects Patients

Verapamil is a medication used to treat irregular heartbeats, chest pain, and high blood pressure. It works by blocking certain channels in the heart muscle, reducing the strength of the heart's contractions. Depending on the formulation, verapamil may need to be taken 3-4 times per day or once daily. People with severe heart problems should not take verapamil as it could make their condition worse.

How Calan Sr works in the body

Verapamil works by blocking L-type calcium channels, which are found in muscle and heart tissue. This blocks calcium from entering the cell, which reduces the force with which the heart has to push, lowering blood pressure and helping with angina. It also slows down the electrical activity of the heart, helping to control heart rate in those with arrhythmia. Verapamil may also work on other calcium channels, potassium channels, and adrenergic receptors.

When to interrupt dosage

The amount of Calan Sr is contingent upon the determined issue, including Tachycardia, Ventricular, Unstable Angina Pectoris and Vasospastic Angina. The quantity of dosage revolves around the approach of delivery as highlighted in the table below.

Condition

Dosage

Administration

Angina, Stable

180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL

Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection - Intravenous, Injection, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous

Vasospastic Angina

180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL

Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection - Intravenous, Injection, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous

Heart Rate

180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL

Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection - Intravenous, Injection, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous

prophylaxis of Cluster headaches

180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL

Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection - Intravenous, Injection, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous

Angina, Unstable

180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL

Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection - Intravenous, Injection, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous

Cluster Headache

180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL

Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection - Intravenous, Injection, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous

Hypertensive disease

180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL

Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection - Intravenous, Injection, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous

Tachycardia, Ventricular

180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL

Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection - Intravenous, Injection, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous

Tachycardia, Supraventricular

180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL

Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection - Intravenous, Injection, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous

Atrial Fibrillation or Flutter

180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL

Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection - Intravenous, Injection, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous

Warnings

Calan Sr has eleven disclaimers and should not be used for the conditions given in the table below.

Calan Sr Contraindications

Condition

Risk Level

Notes

Atrioventricular Block

Do Not Combine

Ventricular Tachycardia

Do Not Combine

Atrial Fibrillation

Do Not Combine

Shock, Cardiogenic

Do Not Combine

accessory bypass tract

Do Not Combine

Heart Failure

Do Not Combine

Pulse Frequency

Do Not Combine

Sick Sinus Syndrome

Do Not Combine

Bradycardia

Do Not Combine

Hypotension

Do Not Combine

Pulse Frequency

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Verapamil may interact with Pulse Frequency

There are 20 known major drug interactions with Calan Sr.

Common Calan Sr Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The serum concentration of Abemaciclib can be increased when it is combined with Verapamil.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Verapamil.

Acepromazine

Major

Verapamil may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Verapamil.

Alfuzosin

Major

Verapamil may increase the hypotensive activities of Alfuzosin.

Calan Sr Toxicity & Overdose Risk

The lowest toxic dose of verapamil for women is 14.4 mg/kg and for men is 3.429 mg/kg. The lethal dose of verapamil for rats and mice is 150 mg/kg and 163 mg/kg respectively. There is no antidote for verapamil overdose, so treatment focuses on managing the symptoms, which can include low blood pressure, slow heartbeat, and irregular heart rhythm. In cases of large overdoses (up to 9 grams), non-cardiogenic pulmonary edema has been reported. To treat an overdose, doctors may use medications to empty the stomach, cathartics and

image of a doctor in a lab doing drug, clinical research

Calan Sr Novel Uses: Which Conditions Have a Clinical Trial Featuring Calan Sr?

34 active studies are currently being conducted to investigate the potential of Calan SR in alleviating symptoms of Chronic Stable Angina Pectoris, Tachycardia, Ventricular and Paroxysmal Supraventricular Tachycardia (PSVT).

Condition

Clinical Trials

Trial Phases

Cluster Headache

2 Actively Recruiting

Phase 1, Phase 2

Heart Rate

0 Actively Recruiting

Tachycardia, Supraventricular

2 Actively Recruiting

Phase 3, Phase 2

Angina, Unstable

2 Actively Recruiting

Not Applicable

prophylaxis of Cluster headaches

0 Actively Recruiting

Vasospastic Angina

1 Actively Recruiting

Phase 2, Phase 3

Angina, Stable

0 Actively Recruiting

Atrial Fibrillation or Flutter

0 Actively Recruiting

Tachycardia, Ventricular

0 Actively Recruiting

Hypertensive disease

27 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Calan Sr Reviews: What are patients saying about Calan Sr?

5

Patient Review

6/24/2009

Calan Sr for Migraine Prevention

I've been taking 120 mg/day for the past 6 months as a prophylactic measure against severe headaches. So far, it's working great--I've only had two headaches in that time.

5

Patient Review

4/22/2009

Calan Sr for Migraine Prevention

Finally found a medication that works for my son's migraines! We've been using it for two months now with no issues.

4

Patient Review

2/15/2008

Calan Sr for Atrial Flutter

I still have some heart rate issues and bouts of depression, but since I started taking Calan SR Oral, I haven't had a single migraine. That's been an incredible relief for me.

3.3

Patient Review

8/4/2010

Calan Sr for High Blood Pressure

I was originally prescribed this medication to help with my Raynauld's condition. However, since taking it I have developed high blood pressure and high cholesterol. I'm otherwise healthy for my age. Could there be an underlying condition that I am unaware of?

2

Patient Review

6/19/2009

Calan Sr for Cluster Headache Prevention

Unfortunately, this medication not only failed to alleviate my boyfriend's cluster headaches, but it also had the adverse effect of slowing his heart rate. I would not recommend this drug to anyone seeking relief from cluster headaches.

1

Patient Review

11/7/2012

Calan Sr for Migraine Prevention

I started taking this medication for about a month to help with my migraines. However, after starting this medication I began experiencing vertigo so severe that I would pass out. This happened on three separate occasions and my doctor took me off the medication immediately.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about calan sr

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of CALAN?

"The following effects may occur: dizziness, slow heartbeat, constipation, nausea, headache, or tiredness. If you experience any of these effects for an extended period of time, or if they worsen, contact your doctor or pharmacist. To reduce your risk of dizziness and lightheadedness, get up slowly when rising from a sitting or lying position."

Answered by AI

Is Calan SR a beta blocker?

"The drug Calan SR is used to treat hypertension, angina, and certain heart rhythm disorders. It works by relaxing the muscles of the heart and blood vessels."

Answered by AI

Is Calan SR the same as verapamil?

"CALAN SR is a drug that inhibits the influx of calcium ions, slowing down the body's channels or calcium ion antagonist. CALAN SR is taken orally as a light green, capsule-shaped pill that is scored and film-coated."

Answered by AI

What is Calan SR used for?

"Verapamil can be used to lower high blood pressure, which in turn can help to prevent strokes, heart attacks, and kidney problems. Verapamil belongs to a class of drugs known as calcium channel blockers. These drugs work by relaxing blood vessels so that blood can flow more easily."

Answered by AI

Clinical Trials for Calan Sr

Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Image of U Health in Miami, United States.

Cuffless PPG Monitor for High Blood Pressure

18+
All Sexes
Miami, FL

This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake/Asleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.

Waitlist Available
Has No Placebo

U Health (+1 Sites)

Ziad Zoghby, M.D., M.B.A.

Biobeat Technologies Ltd.

Have you considered Calan Sr clinical trials?

We made a collection of clinical trials featuring Calan Sr, we think they might fit your search criteria.
Go to Trials
Image of Tampa General Hospital in Tampa, United States.

Fasting for Myocardial Infarction

18+
All Sexes
Tampa, FL

The goal of this clinical trial is to find out whether fasting is necessary before urgent inpatient cardiac catheterizations. For patients presenting with urgent heart-related pain or even mild heart attacks, researchers want to know whether eating and drinking before their procedure improves comfort without raising the risk of complications. The study will answer: * Does eating and drinking before the procedure improve patient comfort? * Does it increase the risk of adverse events like vomiting, aspiration (food or liquid entering the lungs), breathing problems, or death, etc? Participants will be randomly assigned to either: * A standard fasting group (no food for 6 hours, no clear liquids for 2 hours), or * A no-fasting group (able to eat and drink as usual). Patients will complete brief surveys before the procedure to assess comfort and satisfaction. Researchers will also review medical records weekly and 30 days later to monitor for safety outcomes.

Recruiting
Has No Placebo

Tampa General Hospital

Samip Vasaiwala, MD

Have you considered Calan Sr clinical trials?

We made a collection of clinical trials featuring Calan Sr, we think they might fit your search criteria.
Go to Trials
Image of University of Alberta in Edmonton, Canada.

Egg White Powder for High Blood Sugar and High Blood Pressure

18 - 70
All Sexes
Edmonton, Canada

Bioactive peptides derived from food proteins show potential for improving human health. One of such promising peptides is namely IRW made from egg white hydrolysate and composed of three peptides. This is a feasibility study to assess the acute effect of IRW in egg white hydrolysate for the management of high sugar and blood pressure. Participants at high risk of type 2 diabetes (T2D) or having T2D will undergo 4 consecutive treatments of 1 day each (randomly), during which they will consume a standardized breakfast with a smoothie containing different protein powders. Each treatment will be separated by a minimum of 1-week. Participants in the healthy control group will undergo 1 treatment only (one day).

Phase 1
Recruiting

University of Alberta

Jianping Wu, PhD

Image of Northern Arizona University in Flagstaff, United States.

CardioCare Quest for High Blood Pressure

18+
All Sexes
Flagstaff, AZ

This project aims to address healthcare disparities among Navaho people diagnosed with hypertension or prehypertension through three main objectives. Firstly, it identifies and shares insights on healthcare access disparities affecting Navaho individuals experiencing nonadherence to hypertension treatment. Secondly, the proposal develops a telehealth solution based on factors identified as knowledge gaps caused by healthcare access disparities in hypertension management; we will use the factors to design a series of engaging minigames that can be incorporated into the larger CardioCare Quest. These minigames will be co-designed with end users and clinicians. Finally, the proposal conducts comprehensive qualitative and quantitative assessments of user experiences, perceptions, and challenges with CardioCare Quest.

Recruiting
Has No Placebo

Northern Arizona University (+1 Sites)

Tochukwu Ikwunne, PhD

Have you considered Calan Sr clinical trials?

We made a collection of clinical trials featuring Calan Sr, we think they might fit your search criteria.
Go to Trials